role of biomarkers in management of prostate cancer dr. angela amayo specialist pathologist 13 th...

18
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Upload: alison-wilson

Post on 12-Jan-2016

216 views

Category:

Documents


4 download

TRANSCRIPT

Page 1: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Role of Biomarkers in Management of Prostate

Cancer

Dr. Angela Amayo

Specialist Pathologist

13th April 2012

Page 2: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Outline

Review

• Performance characteristics of PSA markers

• Limitations of PSA

• Guidelines for clinical utility of PSA in screening and treatment monitoring.

Page 3: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Tumour Biomarkers

• Substances usually found in body fluids.

• Used to determine the presence of tumours.

• Are produced by

- tumour cells, or

- host cells in response to presence of tumour

Page 4: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Prostate Specific Antigen (PSA)

• A protease enzyme produced by prostatic epithelial cells.

• Circulates in blood in free form or bound to α1- antichymotrypsin.

• Serum reference values < 2ug/L

• Elevations found in prostatitis, BPH and Prostate cancer.

• PSA use reported to contribute greatly to early Ca prostate diagnosis.

Page 5: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Criteria for assessing usefulness of tumour biomarkers:-

• High sensitivity – detectable when only few cancer cells present.

Sensitivity = TPos TPos+ FNeg

• High specificity – not detectable in healthy individuals or in non-malignant disease.

Specificity = TNeg TNeg + FPos.

Page 6: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Clinical Utility of PSA

• Screening – Widespread use

• Diagnosis – Limited use

• Prognosis – Limited usefulness.

• Treatment Monitoring - Indicated

Page 7: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

PSA Performance characteristics in screening

At cut-off of 4 ug/L: - Sensitivity 78% - Specificity 33%.

Causes of low specificity:• Elevations in non malignant situations BPH Prostatitis Prostate surgical procedures

Page 8: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Approaches to increase PSA specificity1. Use of free PSA• For PSA 4-10ug/L• Estimate percent free PSA. • Low % free PSA associated with higher

likelihood of cancer.

% Free PSA Cancer Risk

> 25% <10%

< 10% 56%

Page 9: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Approaches to increase PSA specificity

2. Use of age dependent reference values.

• Improves detection of cancer in younger adults.

Age Reference values

40 – 49 yrs 0 – 2.5 ug/L

50 – 59 yrs 0 – 3.5ug/L

60 – 69 yrs 0 – 4.5ug/L

Page 10: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Approaches to increase PSA specificity

3. Use of PSA dynamics

• Includes PSA velocity and PSA doubling time. Based on annual PSA testing.

• Measures rate of PSA increase over time.

• Highest increase rate in cancer.

• In PSA >4, increase >0.75ug/L/yr significant

• In PSA <4, increase > 0.5ug/L/yr significant.

Page 11: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Purpose of PSA screening

To identify those with high cancer risk who should undergo diagnostic biopsy.

Page 12: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

PSA Screening approaches

Authority Recommendations

American Cancer Society Annual Screening From 50 – 76 years Afr Ame from 45 years

American College of Physicians

Above with proviso – inform clients of risks and benefits. Clients make informed choice.

Kenya ?

Page 13: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Use of PSA in treatment monitoring

1. Assessment of completeness of surgery

• Following prostatectomy, PSA levels should be < 2ug/L.

• PSA should be measured after 6 weeks (allow clearance of PSA released during surgery).

• Persistent elevations may suggest residual tumour or metastatic disease

Page 14: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Use of PSA in treatment monitoring

2. Active surveillance or follow up after surgery/ radiation

• Important use of tumour biomarker

• Evaluates success of therapy

• Aid in early detection of recurrence

Page 15: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Biomarkers in treatment monitoring • Decrease in marker level to normal

indicates effective treatment.

• Persistent elevation of marker indicates residual disease or metastases.

• Renewed increase after period of normal indicates recurrence of tumour.

• Requires serial estimations of biomarkers.

• Method used for testing important for interpretation of serial results.

• Same analytical method should be used.

Page 16: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Interpretation of biomarker during treatment monitoring

• No change- Marker does not fall to <50% of pretreatment values.

• Improvement- Marker falls to < 50% of pretreatment values.

• Response – Marker falls to <10% pretreatment values.

• Complete response- Marker falls to normal reference value.

Page 17: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

SUMMARY• PSA is an organ specific tumour

biomarker.• Specificity of PSA for Ca Prostate is low• Knowledge of the performance

characteristics is important.• Approaches can be used to improve

specificity.• Useful role for PSA in treatment

monitoring.• Analytical method used important for

interpretation of results.

Page 18: Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012

Thank You